Equities

Suzhou Zelgen Biopharmaceuticals Co Ltd

688266:SHH

Suzhou Zelgen Biopharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)68.60
  • Today's Change0.44 / 0.65%
  • Shares traded3.08m
  • 1 Year change+40.34%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,2471,0461,202
Total Receivables, Net11710699
Total Inventory1119952
Prepaid expenses464153
Other current assets, total------
Total current assets2,5201,2921,406
Property, plant & equipment, net275255201
Goodwill, net------
Intangibles, net6991116
Long term investments5.9910.0010.00
Note receivable - long term------
Other long term assets------
Total assets2,8871,6681,746
LIABILITIES
Accounts payable138152118
Accrued expenses846852
Notes payable/short-term debt794390132
Current portion long-term debt/capital leases636444
Other current liabilities, total575535
Total current liabilities1,135729381
Total long term debt299348
Total debt886547224
Deferred income tax9.581316
Minority interest122857
Other liabilities, total684548
Total liabilities1,254909550
SHAREHOLDERS EQUITY
Common stock265240240
Additional paid-in capital3,3532,2222,205
Retained earnings (accumulated deficit)(1979)(1700)(1243)
Treasury stock - common------
Unrealized gain (loss)(4.01)----
Other equity, total(1.94)(2.84)(6.32)
Total equity1,6337591,196
Total liabilities & shareholders' equity2,8871,6681,746
Total common shares outstanding265240240
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.